阿森迪斯制药(Ascendis Pharma A/S,股票代码ASND)昨日盘中大涨5.19%,引发市场广泛关注。
该公司之所以获得资金青睐,主要有以下两方面原因:其一,该公司新鲜出炉的2024财年第三财季财报显示净利润同比大涨38.07%至-1.09亿美元,营业收入也同比增长21.59%至6,353万美元,业绩表现出色,获得市场认可;其二,截止目前共有14家机构对该股给予买入评级,目标均价194.76美元,高于现价近50%,体现出机构对其长期发展前景的看好。
作为一家生物科技公司,阿森迪斯制药凭借其独有的Transcon技术开发多款新药,产品线丰富,满足患者医疗需求。目前该公司的业务遍布北美、中国和欧洲,市场空间广阔。随着各款新药产品线的不断推出,公司将持续受益于收入与净利润的增长。本次财报与机构评级的利好作用下,投资者对该股长期增长动力更加乐观,因而推动股价大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.